The History of Patenting Genetic Material

Annual Review of Genetics

Volumn 49, Issue , 2015, Pages 161-182

  Sherkow, Jacob S ^a   Greely, Henry T ^b  

^a NEW YORK LAW SCHOOL   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

BRCA; Genetics; History; Intellectual property; Law; Myriad; Patents

Indexed keywords

ARTICLE; BREAST CANCER; CANCER RISK; COURT; DEVELOPING COUNTRY; GENE SEQUENCE; GENETICS; HUMAN; INDIGENOUS PEOPLE; MOLECULAR PATHOLOGY; NONHUMAN; OVARY CANCER; PATENT; POLITICS; PRIORITY JOURNAL; TRANSGENIC PLANT; ANIMAL; BIOLOGY; GENE; HISTORY; JURISPRUDENCE; LEGISLATION AND JURISPRUDENCE; PUBLIC OPINION; TRANSGENIC ANIMAL; UNITED STATES;

BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BIOLOGY; BRCA1 PROTEIN; BRCA2 PROTEIN; GENES; GENETICS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PATENTS AS TOPIC; PLANTS, GENETICALLY MODIFIED; PUBLIC OPINION; SUPREME COURT DECISIONS; UNITED STATES;

EID: 84948738507     PISSN: 00664197     EISSN: 15452948     Source Type: Book Series    
DOI: 10.1146/annurev-genet-112414-054731     Document Type: Article

References (138)

1. Adams MD, Kelley JM, Gocayne JD, Dubnick M, Polymeropoulos MH, et al. 1991. Complementary DNA sequencing: expressed sequence tags and Human Genome Project. Science 252:1651-56
2. Allison JR, Lemley MA, Moore KA, Trunkey RD. 2004. Valuable patents. Georget. Law J. 92:435-77
3. Andrews LB, Paradise J. 2005. Gene patents: the need for bioethics scrutiny and legal change. Yale J. Health Policy Law Ethics 5:403-12
4. Association for Molecular Pathology v. Myriad Genetics. 2011. 653 F.3d 1329 (Fed. Cir.)
5. Association for Molecular Pathology v. Myriad Genetics, Inc. 2012. 132 S. Ct. 1794
6. Association for Molecular Pathology v. Myriad Genetics, Inc. Petition for Certiorari. 2012. 2013 West Law 1850746
7. Association for Molecular Pathology v. Myriad Genetics. Brief for Amicus Curiae Eric S. Lander in Support of Neither Party. 2013. https://www.wsgr.com/PDFSearch/lander.pdf
8. Association for Molecular Pathology v. Myriad Genetics, Inc. 2013. 133 S. Ct. 2107
9. Association for Molecular Pathology v. US Patent and Trademark Office. 2010. 702 F. Supp. 2d 181 (S.D.N.Y.)
10. Baltimore D. 1970. RNA-dependent DNA polymerase in virions of RNA tumour viruses. Nature 226:1209-11
11. Barfield C, Calfee JE. 2007. Biotechnology and the Patent System: Balancing Innovation and Property Rights. Washington, DC: Am. Enterp. Inst. Press
12. Barton JH. 2002. Research-tool patents: Issues for health in the developing world. Bull.WHO80(2):121-25
13. Beauchamp C. 2013. Patenting nature: a problem of history. Stanf. Technol. Law Rev. 16:257-312
14. Burk DL. 2014. The curious incident of the Supreme Court in Myriad Genetics. Notre Dame Law Rev. 90:505-542
15. Burk DL, Lemley MA. 2002. Is patent law technology specific? Berkeley Technol. Law J. 17:1155-206
16. Burrows B. 1997. Campaigns against life patenting. Synthesis/Regeneration
17. http://www.greens. org/s-r/14/14-18.html
18. Cann HM, de Toma C, Cazes L, Legrand M-F, Morel V, et al. 2002. A human genome diversity cell line panel. Science 296:61-62
19. Cavalli-Sforza LL. 2005. The Human Genome Diversity Project: past, present and future. Nat. Rev. Genet. 6:333-40
20. Chandrasekharan S, Heaney C, James T, Conover C, Cook-Deegan R. 2010. Impact of gene patents and licensing practices on access to genetic testing for cystic fibrosis. Genet. Med. 12:S194-211
21. Charnas R. 2002. "No patents on life" working group update. Counc. Responsib. Genet. http://www. councilforresponsiblegenetics.org/ViewPage.aspx?pageId=169
22. Cheon JY, Mozersky J, Cook-Deegan R. 2014. Variants of uncertain significance in BRCA: A harbinger of ethical and policy issues to come? Genome Med. 6:121
23. Cho MK, Illangasekare S, Weaver MA, Leonard DGB, Merz JF. 2003. Effects of patents and licenses on the provision of clinical genetic testing services. J. Mol. Diagn. 5(1):3-8
24. Cohen JE, Lemley MA. 2001. Patent scope and innovation in the software industry. Calif. Law Rev. 89:1-57
25. Cohen SN. 2013. DNA cloning: A personal view after 40 years. PNAS 110:15521-29
26. Colaianni A, Chandrasekharan S, Cook-Deegan R. 2010. Impact of gene patents and licensing practices on genetic testing and carrier screening for Tay-Sachs and Canavan disease. Genet. Med. 12:S5-14
27. Colliver V. 2013. Ruling on gene patents praised. San Francisco Chronicle, June 14, p. A1
28. Consolidated Appropriations Act. 2004. Pub. L. No. 108-199, §634, 118 Stat. 3
29. Convention on Biodiversity. 1992. 1760 UNTS 79; 31 ILM 818
30. Cook-Deegan R, Heaney C. 2010. Patents in genomics and human genetics. Annu. Rev. Genomics Hum. Genet. 11:383-425
31. Coughlin SM. 2006. TheNewman application and theUSPTO's unnecessary response: the patentability of humans and human embryos. 5 Chic.-Kent J. Intell. Prop. 90:105
32. Crichton M. 2006. Next. New York: HarperCollins
33. Crichton M. 2007. Patenting life. New York Times, Feb. 13, p. A23
34. Czarnetzky JM. 1988. Altering nature's blueprints for profit: patenting multicellular animals. Va. Law Rev. 74:1327-62
35. D'Arcy v. Myriad Genetics Inc. 2014. FCAFC 115
36. Diamond v. Chakrabarty. 1980. 447 US 303
37. Directive 98/44/EC Eur. Parliament Counc. 6th July 1998
38. Dolan v. City of Tigard. 1994. 512 US 374
39. ECT Group. 1995. US government dumps the Hagahai patent. http://www.etcgroup.org/content/usgovernment-dumps-hagahai-patent
40. Eisenberg RS. 1987. Proprietary rights and the norms of science in biotechnology research. Yale Law J. 97:177-231
41. Eisenberg RS. 2007. The role of the FDA in innovation policy. Mich. Telecom. Technol. Law Rev. 13:345-87
42. Eisenberg RS. 2012. Patents and regulatory exclusivity. In The Oxford Handbook of the Economics of the Biopharmaceutical Industry, ed. PM Danzon, S Nicholson, pp. 167-98. Oxford, NY: Oxford Univ. Press
43. Locke JC,LarewHGIII, Walter JF. 1994. Method for controlling fungi on plants by aid of a hydrophobic extracted neem oil. Eur. Patent No. EP0436257
44. File history of U.S.S.N 08/993,564 at Office Action mailed on August 2, 2004
45. Free the Data. 2015. Free the data. Washington, DC: Genet. Alliance. http://www.free-The-data.org/ clinicians
46. Friedlaender J. 1996. Genes, people, and property: Furor erupts over genetic research on indigenous groups. Cult. Surviv. Q. 20(2):22-25
47. Gold ER, Carbone J. 2010. Myriad Genetics: In the eye of the policy storm. Genet. Med. 12:S39-70
48. Greely HT. 1997. The ethics of the Human Genome Diversity Project: The North American Regional Committee's proposed Model Ethical Protocol. In Human DNA: Law and Policy -International and Comparative Perspectives, ed. BM Knoppers, pp. 239-56. Boston: Kluwer Law Int
49. Greely HT. 1999. The overlooked ethics of the Human Genome Diversity Project. Polit. Life Sci. 18:297-99
50. Greely HT. 2001. Human genome diversity: What about the other human genome project? Nat. Rev. Gen. 2:222-27
51. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, et al. 1994. Linkage of early-onset familial breast cancer to Chromosome 17q21. Science 250:1684-89
52. Hanley CJ. 1996. A case of good research or "genetic colonialism." Associated Press, April 21
53. Harburg EY, Arlen H. 1939. Ding dong! The witch is dead. The Wizard of Oz. Lyrics. http://www. stlyrics.com/lyrics/thewizardofoz/dingdongthewitchisdead.htm
54. Harry D. 1995. The Human Genome Diversity Project and its implications for indigenous peoples. Information About Intellectual Property Rights No. 6, at Indigenous Peoples Council on Biocolonialism at http://www.ipcb.org/publications/briefing-papers/files/hgdp.html, accessed May 4, 2015
55. Harvard College v. Canada (Commissioner of Patents). 2002. 4 SCR 45, 2002 SCC 76
56. Healy B. 1992. On gene patenting. N. Engl. J. Med. 327:664-68
57. Heled Y. 2014. On patenting human organisms or how the abortion wars feed into the ownership fallacy. Cardozo Law Rev. 36:241-98
58. HellerMA, EisenbergRS. 1998. Can patents deter innovation?The anticommons in biomedical research. Science 280:698-701
59. Hellerer U, Jarayaman KS. 2000. Greens persuade Europe to revoke patent on neem tree. Nature 405:266-67
60. H.R. 3119, 100th Congr., 1st sess. 1987 [Rose bill]
61. H.R. 4970, 100th Congr., 1st sess. 1989 [Kastenmeier bill]
62. H.R. 977, 110th Congr., 1st sess. 2007 [Becerra bill]
63. In re Allen. 1987. 2 USPQ 2d (BNA), 1425 (Board. Patent Appeal Int.)
64. In re BRCA1-&BRCA2-Based Hereditary Cancer Test Patent Litig. 2014. 3 F. Supp. 3d 1213 (D. Utah)
65. In re BRCA1-&BRCA2-Based Hereditary Cancer Test Patent Litig. 2014. 774 F.3d 755 (Fed. Cir.)
66. In re Fisher. 2005. 421 F.3d 1365 (Fed. Cir.)
67. Kevles DJ. 1994. Ananda Chakrabarty wins a patent: biotechnology, law, and society. Hist. Stud. Phys. Biol. Sci. 25(Pt. 1):111-35
68. Khorana HG, Buchi H, Ghosh H, Gupta N, Jacob TM, et al. 1966. Polynucleotide synthesis and the genetic code. Cold Spring Harb. Symp. Quant. Biol. 31:39-49
69. Kitch EM. 1986. Patents: monopolies or property rights? Res. Law Econ. 8:31-49
70. Kolata G. 2013. DNA project aims to make public a company's data on cancer genes. New York Times, April 12, p. A14
71. Kreeger KY. 1996. Proposed Human Genome Diversity Project still plagued by controversy and questions. Scientist 10:1-8
72. Leder P, Stewart T. 1985. Transgenic animals. Can. Patent No. 1341442
73. Leder P, Stewart T. 1986. Method for producing transgenic animal. Eur. Patent No. EP0169672
74. Ledford H. 2013. Seed-patent case in Supreme Court. Nature 494:289-90
75. Lemley MA, Shapiro C. 2007. Patent holdup and royalty stacking. Tex. Law Rev. 85:1991-2049
76. Mayo Collaborative Services v. Prometheus Laboratories. 2012. 566 U.S., 132 S. Ct. 1289
77. Mehlman MJ. 2004. Moore v. Regents of the University of California. In Property Stories. New York: Found. Press. 2nd ed
78. Merges R. 1994. Intellectual property rights and bargaining breakdown: the case of blocking patents. Tenn. Law Rev. 62:75-106
79. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, et al. 1994. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71
80. Miller WL. 1979. Use of recombinant DNA technology for the production of polypeptides. Adv. Exp. Med. Biol. 118:153-74
81. Moore v. Board of Regents of the Univ. of Calif. 1990. 51 Cal. 3d 120; 271 Cal. Rptr. 146; 793 P.2d 479
82. Mossoff A. 2009. Exclusion and exclusive use in patent law.Harv. J. Law Technol. 22:321-79
83. Mowery DC, Nelson RR, Sampat BN, Ziedonis AA. 2001. The growth of patenting and licensing by US universities: an assessment of the effects of the Bayh-Dole act of 1980. Res. Policy 30:99-119
84. Natl. Res. Counc. 1997. Intellectual Property Rights and Research Tools in Molecular Biology. Washington, DC: Natl. Acad. Press
85. Natl. Res. Counc. 2006. Reaping the Benefits of Genomic and Proteomic Research: Intellectual Property Rights, Innovation and Public Health.Washington, DC:Natl. Acad. Press
86. Nuffield Counc. Bioethics. 2002. The Ethics of Patenting DNA: A Discussion Paper. London: Nuffield Counc. Bioethics. http://nuffieldbioethics.org/project/patenting-dna
87. Papadopoulos S. 2003. Evolving paradigms in biotech IPO valuations. Bioentrepreneur. http://www. nature.com/bioent/2003/030101/full/nbt0601supp-BE18.html
88. Parke-Davis &Co. v. H.K. Mulford. 1911. 189 F. 95 (S.D.N.Y.)
89. Patents and the Constitution: Hearings Before the Subcomm. on Courts, Civil Liberties and the Administration of Justice of the House Comm. on the Judiciary. 1987. 100th Congr., 1st sess. 3
90. Pieroni JP. 1999. The patentability of expressed sequence tags. Fed. Cir. B. J. 9:401-16
91. PwC (PriceWaterhouseCoopers). 2014. 2014 Patent Litigation Study: As Case Volume Leaps,Damages Continue General Decline. http://www.pwc.com/en-US/us/forensic-services/publications/assets/2014-patent-litigation-study.pdf
92. Quigg DJ. 1987. Policy statement on the patentability of animals. 1077 Off. Gaz. Pat. Off. 24 (7 April)
93. RimmerM. 2008. Intellectual Property and Biotechnology: Biological Inventions. Northampton,MA: Edward Elgar
94. Riordan T. 1995. Patents: A recent patent on a Papau New Guinea tribe's cell line prompts outrage and charges of "biopiracy." New York Times, Nov. 27
95. Roin BR. 2009. Unpatentable drugs and the standards of patentability. Tex. Law Rev. 87:503-70
96. Sanger F, Nicklen S, Coulson AR. 1977. DNA sequencing with chain-terminating inhibitors. PNAS 74:5463-67
97. Schwartz J, Pollack A. 2010. Judge invalidates human gene patents. New York Times, March 29, p. B1
98. Scott Paper Co. v. Marcalus Mfg. Co. 1945. 326 US 811
99. Secretary's Advisory Committee on Genetics, Health, and Society. 2010. Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests.Washington, DC: DHHS
100. Seeking Alpha. 2015. Myriad Genetics' (MYGN) CEO Peter Meldrum on Q2 2015 results -earnings call transcript. http://seekingalpha.com/article/2881086-myriad-genetics-mygn-ceo-peter-meldrum-onq2-2015-results-earnings-call-transcript
101. Seymore S. 2010. The teaching function of patents. Notre Dame Law Rev. 85:621-69
102. Sherkow JS. 2014. The natural complexity of patent eligibility. Iowa Law Rev. 99:1137-96
103. Siva N. 2009. Myriad wins BRCA1 row. Nat. Biotechnol. 27:8
104. Skloot R. 2010. The Immortal Life of Henrietta Lacks. New York: Crown
105. Stevens AJ. 2004. The enactment of Bayh-Dole. J. Technol. Transf. 29:93-99
106. T 0019/90 (Eur. Patent Off. Board Appeal, Mar. 10, 1980)
107. T 0315/03 (Eur. Patent Off. Board Appeal, June 7, 2004)
108. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, et al. 1996. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat. Genet. 12:333-37
109. Terry S. 2010. Why banning patents would hurt patients. GeneWatch 5(2). http://www. councilforresponsiblegenetics.org/genewatch/GeneWatchPage.aspx?pageId=300
110. TheUse of Human BiologicalMaterials in theDevelopment of Biomedical Products:Hearings Before the Subcomm. on Investigations and Oversight of the House Comm. on Science and Technology. 1985. 99th Congr., 1st sess. 241
111. US Congr., Off. Technol. Assess. 1989. New Developments in Biotechnology: Ownership of Human Tissues and Cells -Spec. Rep. OTA-BA-337. Washington, DC: GPO
112. US Food Drug Adm. 2014. Draft Guidance for Industry, Food and Drug Administration Staff, and Clinical Laboratories: Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs)
113. US Food Drug Adm. 2014. FDA approves Lynparza to treat advanced ovarian cancer. http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm427554.htm
114. US National Institutes of Health. 1998. Report of the National Institutes of Health (NIH) Working Group on Research Tools. Bethesda, MD: US NIH. https://www.mmrrc.org/about/NIH-research-tools-policy/, accessed May 4, 2015
115. Gorana HG. 1957. Synthesis of nucleoside phosphates. US Patent No. 2795580
116. Heidelberger C, Duschlasky R. 1957. 5-Fluorouracil. US Patent No. 2802005
117. Spiegelman S, Haruna I. 1972. Synthesis in vitro of nucleic acids and products used therein and products produced therefrom. US Patent No. 3661893
118. Jachertz D. 1974. Process for the enzymatic reproduction of informationally active RNA. US Patent No. 3785926
119. Fare LR, Goore M, Naylor JF III, Valenta JR. 1974. Antiviral complex of RNA and polysaccharide. US Patent No. 3821193
120. Cohen SN, Boyer HW. 1980. Process for producing biologically functional molecular chimera. US Patent No. 4237224
121. Manis JJ. 1981. Plasmid and process of isolating same. US Patent No. 4273875
122. Wu RJ, Bahl CP, Narang SA. 1982. Oligonucleotides useful as adaptors in DNA cloning, adapted DNA molecules, and methods of preparing adaptors and adapted molecules. US Patent No. 4321365
123. Brassfield RW. 1982. Airlift type dredging apparatus. US Patent No. 4322897
124. BosWA. 1982. Cutter head with adjustable suction nozzle. US Patent No. 4322898
125. Goodman HM, Shine J, Seeburg PH. 1982. RecombinantDNA transfer vectors. US Patent No. 4363877
126. Olsen RH. 1983. DNA fragments for forming plasmids. US Patent No. 4418194
127. Roland J, Reppelin M, Seigneurin L. 1984. Preparation of aromatic(aliphatic nitriles. US Patent No. 4438042
128. Olsen RH. 1985. Molecular cloning vectors for use in gram-negative bacteria. US Patent No. 4508827
129. Leder P, Stewart TA. 1988. Transgenic non-human mammals. US Patent No. 4736866
130. US Patent Appl. No. 08/933,564 (submitted Dec. 18, 1997)
131. US Patent Trademark Off. 1998. Facts on patenting life forms having a relationship to humans. http://www. uspto.gov/about-us/news-updates/facts-patenting-life-forms-having-relationship-humans
132. von der Ropp A, Taubman T. 2006. Bioethics and patent law:The case ofMyriad. WIPO Mag. 2006(4):8-9
133. Werth B. 2013. A tale of two drugs. Technol. Rev., Oct. 22
134. Whoriskey P. 2009. Monsanto's dominance draws antitrust inquiry. Washington Post, Nov. 29
135. Wired. 1999. Genentech pays off UCSF. Wired. http://archive.wired.com/science/discoveries/news/ 1999/11/32655
136. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, et al. 1995. Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-92
137. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, et al. 1994. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265:2088-90
138. Wyatt E. 2013. Obama orders regulators to root out patent trolls. New York Times, June 4, p. B1